rss
Ann Rheum Dis 72:64-71 doi:10.1136/annrheumdis-2011-201247
  • Clinical and epidemiological research

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

Open Access
  1. Josef S Smolen6
  1. 1Division of Rheumatology Allergy and Immunology, UCSD, San Diego, California, USA
  2. 2Division of Rheumatology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
  3. 3Section of Musculoskeletal Disease, University of Leeds, Leeds, UK
  4. 4GPRD, Abbott Laboratories, Ludwigshafen, Germany
  5. 5GPRD, Abbott Laboratories, Abbott Park, Illinois, USA
  6. 6Division of Rheumatology, Medical University of Vienna, Vienna, Austria
  1. Correspondence to Arthur Kavanaugh, UCSD, UCSD, Rheumatology, Allergy, Immunology, 9500 Gilman Drive, MC 0943 La Jolla CA 92093-0943, USA; akavanaugh{at}ucsd.edu
  1. Contributors Abbott Laboratories sponsored this study (NCT00420927), led development of the study design in collaboration with academic investigators, and analysed the primary data. All authors contributed to design, analysis, and interpretation of these data, and reviewed, approved, and decided to publish the manuscript.

  • Accepted 23 March 2012
  • Published Online First 5 May 2012

Abstract

Objective To assess the efficacy and safety of adalimumab plus methotrexate (ADA+MTX) compared with methotrexate monotherapy in achieving stable low disease activity (LDA; disease activity score (DAS28(CRP)) <3.2 at weeks 22 and 26) and clinical, radiographic and functional outcomes in methotrexate-naive patients with early rheumatoid arthritis (RA).

Methods 1032 patients with active RA were randomly assigned 1:1 to ADA+MTX or placebo plus methotrexate (PBO+MTX) for 26 weeks. Treatment modifications were to be made in a subsequent study period based on the achievement of DAS28(CRP) <3.2 at weeks 22 and 26. Post-hoc analyses compared patients achieving stable remission using DAS28 and 2010 ACR/EULAR criteria with those achieving LDA but not remission.

Results Among patients completing 6 months, 44% (207/466) ADA+MTX versus 24% (112/460) PBO+MTX patients achieved stable LDA at weeks 22 and 26 (p<0.001). Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all). The only factor predicting stable LDA was disease activity at week 12. Patients achieving ACR/EULAR remission, particularly in the PBO+MTX group, had some advantage in radiographic outcomes compared with patients who only achieved LDA (but not remission). The overall frequency of adverse events was comparable between groups. There were more serious infections and deaths in the ADA+MTX group, with a possible age effect.

Conclusions Treatment with ADA+MTX was significantly superior to methotrexate alone with respect to clinical, radiographic and functional outcomes in patients with early active RA. Before initiating treatment with adalimumab, individual patient evaluation of the benefit/risk ratio should be carefully considered.

Footnotes

  • Funding This study was funded by Abbott Laboratories.

  • Competing interests AK has provided expert advice to, and/or received research grants from Abbott, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche and UCB. RMF has received research grants and consulting fees or other remuneration from Abbott. PE has provided expert advice and undertaken trials for Abbott, Merck, Pfizer, UCB, Roche and BMS. HK, LR, BG and SS are Abbott employees and may hold stock or options. JSS has received research grants and/or consulting fees or other remuneration from Abbott, Amgen, Astra-Zeneca, BMS, Celgene Centocor-Janssen, Glaxo, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz and UCB.

  • Ethics approval A central institutional review board or independent ethics committee approved the study at each site.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

Open Access

Free sample This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article